We have located links that may give you full text access.
Scoring the 10-year risk of ambulatory disability in multiple sclerosis: the RoAD score.
European Journal of Neurology 2021 March 32
BACKGROUND: Both baseline prognostic factors and short-term predictors of treatment response can influence the long-term risk of disability accumulation in patients with relapsing-remitting multiple sclerosis (RRMS).
OBJECTIVE: To develop and validate scoring system combining baseline prognostic factors and one-year variables of treatment response into a single numeric score predicting the long-term risk of disability.
METHODS: We analyzed two independent datasets of patients with RRMS who started Interferon Beta or Glatiramer Acetate, had an Expanded Disability Status Scale (EDSS) score <4.0 at treatment start and were followed for at least 10 years. The first dataset ("training set") included patients attending three MS Centers in Italy and served as framework to create the so-called RoAD score (Risk of Ambulatory Disability). The second ("validation set") included a cohort of patients followed in Barcelona, Spain, to explore the performance of RoAD score in predicting the risk of reaching an EDSS score≥6.0.
RESULTS: The RoAD score, derived from the training set (n = 1,225), was based on demographic (age) and clinical baseline prognostic factors (disease duration, EDSS) and one-year predictors of treatment response (number of relapses, presence of gadolinium-enhancement and new T2 lesions). The best cut-off score for discriminating patients at higher risk of reaching the disability milestone was ≥4. When applied to the validation set (n = 296), patients with a RoAD score ≥4 had an approximately 4-fold increased risk for reaching the disability milestone (p<0.001).
DISCUSSION: We propose the RoAD score as an useful tool to predict individual prognosis of patients with RRMS to optimize treatment strategy.
OBJECTIVE: To develop and validate scoring system combining baseline prognostic factors and one-year variables of treatment response into a single numeric score predicting the long-term risk of disability.
METHODS: We analyzed two independent datasets of patients with RRMS who started Interferon Beta or Glatiramer Acetate, had an Expanded Disability Status Scale (EDSS) score <4.0 at treatment start and were followed for at least 10 years. The first dataset ("training set") included patients attending three MS Centers in Italy and served as framework to create the so-called RoAD score (Risk of Ambulatory Disability). The second ("validation set") included a cohort of patients followed in Barcelona, Spain, to explore the performance of RoAD score in predicting the risk of reaching an EDSS score≥6.0.
RESULTS: The RoAD score, derived from the training set (n = 1,225), was based on demographic (age) and clinical baseline prognostic factors (disease duration, EDSS) and one-year predictors of treatment response (number of relapses, presence of gadolinium-enhancement and new T2 lesions). The best cut-off score for discriminating patients at higher risk of reaching the disability milestone was ≥4. When applied to the validation set (n = 296), patients with a RoAD score ≥4 had an approximately 4-fold increased risk for reaching the disability milestone (p<0.001).
DISCUSSION: We propose the RoAD score as an useful tool to predict individual prognosis of patients with RRMS to optimize treatment strategy.
Full text links
Related Resources
Trending Papers
Challenges in Septic Shock: From New Hemodynamics to Blood Purification Therapies.Journal of Personalized Medicine 2024 Februrary 4
Molecular Targets of Novel Therapeutics for Diabetic Kidney Disease: A New Era of Nephroprotection.International Journal of Molecular Sciences 2024 April 4
The 'Ten Commandments' for the 2023 European Society of Cardiology guidelines for the management of endocarditis.European Heart Journal 2024 April 18
A Guide to the Use of Vasopressors and Inotropes for Patients in Shock.Journal of Intensive Care Medicine 2024 April 14
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app